Sherman Oaks, CA, United States of America

Abraham Antonio Anderson

This inventor holds 8 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Amgen Inc., Mmrglobal, Inc., Merck Sharp + Dohme Corp.. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Abraham Antonio Anderson. Retrieved from https://idiyas.com/inventor/abraham-antonio-anderson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 50.0

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 63(Granted Patents)

Location History:

Boston, MA (US) (2000)
Berkeley, CA (US) (2001)
Pasadena, CA (US) (2002)
Sherman Oaks, CA (US) (2012 - 2015)
Sherman Hills, CA (US) (2015)

Company Filing History:

Merck Sharp + Dohme Corp.

5. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12310999 - Biomarkers for cancer therapeutics (2025-05-27),

2. 9151761 - Predictive biomarker of survival in the treatment of renal cell carcinoma (2015-10-06),

3. 8945550 - Antibodies and methods for making and using them (2015-02-03),

4. 8465741 - Antibodies and methods for making and using them (2013-06-18),

5. 8168201 - Vaccines (2012-05-01),

6. 6415453 - Low temperature thermal insulation garment utilizing the wearer's exhalant (2002-07-09),

7. 6325776 - Internal by-pass shunt apparatus for the inferior vena cava (2001-12-04),

8. 6148825 - Method of using a dedicated internal shunt and stent for the inferior (2000-11-21),

Title: Abraham Antonio Anderson: Innovator in Cancer Therapeutics

Introduction

Abraham Antonio Anderson is a notable inventor based in Sherman Oaks, CA (US). He has made significant contributions to the field of cancer therapeutics, holding a total of 8 patents. His work focuses on developing biomarkers and treatment methods that enhance the effectiveness of cancer therapies.

Latest Patents

Among his latest patents, Anderson has developed biomarkers that are useful for identifying various cancers responsive to combination therapies. These therapies include pembrolizumab and talimogene laherparepvec. He has also created methods for treating cancers resistant to monotherapy with pembrolizumab. Additionally, his patents address treatment methods for tumors with low CD8+ density and low PD-L1 status. Another significant patent involves predictive biomarkers for survival in renal cell carcinoma, which aids in predicting clinical benefits prior to treatment with VEGFR and Ang2 inhibitors.

Career Highlights

Throughout his career, Anderson has worked with various companies, including Mmrglobal, Inc. His innovative approaches have positioned him as a key figure in the development of cancer treatment methodologies.

Collaborations

Anderson has collaborated with notable individuals in his field, including Bernard Bradley Anderson and Gerhard Johann Frey. Their combined expertise has contributed to advancements in cancer therapeutics.

Conclusion

Abraham Antonio Anderson's work in cancer therapeutics exemplifies the impact of innovation in medicine. His patents and collaborations continue to pave the way for improved cancer treatment options.

Profile summary based on public USPTO records.